Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulinastatin for pediatric sepsis-associated organ damage (ChiCTR2500110759)
ChiCTR2500110759Phase 4Recruiting
- Sponsor
- Children's Hospital of Soochow University
- Start
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in sepsis comparing Test group (ulinastatin) with Control group (placebo saline) (2 arms). Primary endpoint: Composite endpoint: 28-day mortality or persistent organ failure at day 7. Started Oct 2025; status: recruiting.
02
Drugs
ulinastatin
03
Conditions
sepsis
Beyond the preview
Go deeper on ChiCTR2500110759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110759.